5-Amino-1MQ is a small-molecule compound studied as a selective inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme involved in cellular energy metabolism.
🔬 Studied for: Metabolic & Adipose Research
💊 Also studied for: NAD+ Pathway Research
🧪 Not FDA-approved — sold strictly for laboratory research
📈 No standardized human dosage established in published literature
5-Amino-1MQ is a small-molecule compound studied as a selective inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme involved in cellular energy metabolism. It is a small molecule rather than a peptide, but is frequently sold and researched alongside metabolic peptides.
5-Amino-1MQ inhibits NNMT, an enzyme that regulates NAD+ and SAM (S-adenosylmethionine) levels within cells; researchers have proposed that this inhibition shifts cellular energy metabolism toward increased fat-cell metabolism and away from fat storage.
These are effects 5-Amino-1MQ has been studied for in available preclinical and early research — not claims about guaranteed outcomes.
Preclinical rodent studies have investigated 5-Amino-1MQ's effects on fat-cell size and body composition, positioning NNMT inhibition as a novel target distinct from incretin-based (GLP-1) approaches to metabolic research.
Because NNMT activity is tied to cellular NAD+ availability, 5-Amino-1MQ is also studied within the broader NAD+/cellular-energy research space that overlaps with aging and mitochondrial-function research.
Doses used in preclinical rodent studies are documented in that specific research and do not translate to an established human dose. No human dosage of any kind has been clinically validated for 5-Amino-1MQ.
Compound X does not provide dosing recommendations. 5-Amino-1MQ is sold for laboratory research use only and is not intended for human consumption.
5-Amino-1MQ is an early-stage research compound with a published record limited mostly to preclinical rodent studies. It has not been evaluated in human clinical trials, is not FDA-approved, and comprehensive human safety data does not exist.
No. 5-Amino-1MQ is not FDA-approved for any indication and is sold strictly as a research chemical, not a medication or dietary supplement.
Metabolic & Adipose Research — Preclinical rodent studies have investigated 5-Amino-1MQ's effects on fat-cell size and body composition, positioning NNMT inhibition as a novel target distinct from incretin-based (GLP-1) approaches to metabolic research.
In the US, UK, Canada and Australia, 5-Amino-1MQ is generally sold labeled "for research use only, not for human consumption." It is not approved as a dietary supplement or medication in any of these countries.
5-Amino-1MQ research is indexed on PubMed under search terms such as "5-amino-1MQ NNMT inhibitor" and "nicotinamide N-methyltransferase adipose."
Compare current prices, purity testing claims and coupon codes across every vendor Compound X tracks.
New guides, vendor comparisons and compound breakdowns every week.